Werewolf Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Werewolf Therapeutics es Dan Hicklin , nombrado en Oct 2017, tiene una permanencia de 7.08 años. compensación anual total es $1.37M, compuesta por 42.7% salario y 57.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.45% de las acciones de la empresa, por valor de $1.27M. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 5.1 años, respectivamente.
Información clave
Dan Hicklin
Chief Executive Officer (CEO)
US$1.4m
Compensación total
| Porcentaje del salario del CEO | 42.7% |
| Permanencia del CEO | 7.1yrs |
| Participación del CEO | 1.5% |
| Permanencia media de la dirección | 3.9yrs |
| Promedio de permanencia en la Junta Directiva | 5.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?
Nov 14
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?
Jul 31Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Jul 01Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$62m |
| Jun 30 2024 | n/a | n/a | -US$54m |
| Mar 31 2024 | n/a | n/a | -US$42m |
| Dec 31 2023 | US$1m | US$583k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$37m |
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$50m |
| Dec 31 2022 | US$2m | US$530k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$60m |
| Jun 30 2022 | n/a | n/a | -US$62m |
| Mar 31 2022 | n/a | n/a | -US$115m |
| Dec 31 2021 | US$2m | US$498k | -US$202m |
| Sep 30 2021 | n/a | n/a | -US$205m |
| Jun 30 2021 | n/a | n/a | -US$197m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$3m | US$425k | -US$28m |
Compensación vs. Mercado: La compensación total de Dan($USD1.37M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD647.72K).
Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.
CEO
Dan Hicklin (60 yo)
7.1yrs
Permanencia
US$1,366,904
Compensación
Dr. Daniel J. Hicklin, Ph D., also known as Dan, Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019. He serves on its Board of Dire...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 7.1yrs | US$1.37m | 1.45% $ 1.3m | |
| CFO, Treasurer & Assistant Secretary | 3.8yrs | US$815.59k | 0% $ 0 | |
| Chief Medical Officer | 4yrs | US$855.77k | 0% $ 0 | |
| Senior Vice President of Research | less than a year | sin datos | sin datos | |
| Chief Technology Officer | 3.4yrs | US$3.86m | sin datos | |
| Chief Business Officer | 4.3yrs | sin datos | sin datos |
3.9yrs
Permanencia media
64yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de HOWL se considera experimentado (3.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 7.1yrs | US$1.37m | 1.45% $ 1.3m | |
| Independent Chairman of the Board | 7.1yrs | US$104.03k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$78.66k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5yrs | US$62.32k | 0.035% $ 30.4k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board & Director | 6.3yrs | sin datos | 0.032% $ 28.3k | |
| Independent Director | 5.3yrs | US$78.53k | 4.59% $ 4.0m | |
| Independent Director | 3.1yrs | US$65.36k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$72.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
5.1yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de HOWL se considera experimentada (5.1 años de antigüedad promedio).